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Background: Although there are controversial issues (the “American view” and the “  European 
view”) regarding the construct and definition of agoraphobia (AG), this syndrome is well rec-
ognized and it is a burden in the lives of millions of people worldwide. To better clarify the 
role of drug therapy in AG, the authors summarized and discussed recent evidence on pharma-
cological treatments, based on clinical trials available from 2000, with the aim of highlighting 
pharmacotherapies that may improve this complex syndrome.
Methods: A systematic review of the literature regarding the pharmacological treatment of AG 
was carried out using MEDLINE, EBSCO, and Cochrane databases, with keywords individu-
ated by MeSH research. Only randomized, placebo-controlled studies or comparative clinical 
trials were included.
Results: After selection, 25 studies were included. All the selected studies included patients 
with AG associated with panic disorder. Effective compounds included selective serotonin 
reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, 
selective noradrenergic reuptake inhibitors, and benzodiazepines. Paroxetine, sertraline, citalo-
pram, escitalopram, and clomipramine showed the most consistent results, while fluvoxamine, 
fluoxetine, and imipramine showed limited efficacy. Preliminary results suggested the potential 
efficacy of inositol; D-cycloserine showed mixed results for its ability to improve the outcome 
of exposure-based cognitive behavioral therapy. More studies with the latter compounds are 
needed before drawing definitive conclusions.
Conclusion: No studies have been specifically oriented toward evaluating the effect of drugs 
on AG; in the available studies, the improvement of AG might have been the consequence of the 
reduction of panic attacks. Before developing a “true” psychopharmacology of AG it is crucial 
to clarify its definition. There may be several potential mechanisms involved, including fear-
learning processes, balance system dysfunction, high light sensitivity, and impaired visuospatial 
abilities, but further studies are warranted.
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Introduction
Definition
Agoraphobia (AG) is a phobic-anxious syndrome with a long history. The first account 
is credited to Westphal’s classic 1871 description:
“The anxiety is at its most intense in enclosed spaces [...] (The patient) begins to feel 
hot, flustered, tremulous, foolish and panic stricken [...] some patients describe fear of 
developing a panic attack or exhibiting anxiety in the presence of others…”1Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Currently the two officially recognized diagnostic 
manuals used in psychiatric research are the Diagnostic and 
  Statistical Manual for Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR)2 and the International Classification 
of Diseases, 10th revision (ICD-10).3 Each manual gives quite 
a different definition of AG, with only two common features 
that are clearly present:
•	 Marked distress in or avoidance of characteristic situa-
tions such as crowds, public places, and traveling alone 
and away from home;
•	 Experiencing symptoms of anxiety when confronted with 
the feared situation.
The most relevant differences in the diagnostic 
criteria are:
•	 AG is not recognized as an independent disorder in the 
DSM-IV-TR, while in the ICD-10 it is;
•	 There is an explicit reference to PAs or panic-like symp-
toms in the DSM-IV-TR, while in ICD-10 there is not 
(however, the latter requires at least two symptoms of a 
list fully overlapping with the one defined for PAs in the 
DSM-IV-TR);
•	 While the ICD-10 clarifies the excessive or unreasonable 
nature of AG, the DSM-IV-TR does not explicitly state 
this aspect;
•	 There are no explicit exclusion criteria for specific or 
social phobia in the ICD-10, whereas these are stated in 
the DSM-IV-TR.
Given these observations, it is not easy to find a widely 
accepted definition of AG; moreover, there is a current 
debate between those who strictly link AG with PAs4–6 and 
those who view AG as an independent concept.7–9 The authors, 
well aware of this problem, and aware of the use of the DSM 
definition in all pharmacological studies referring to AG in 
some way, will discuss the topic of this review based on the 
DSM-IV-TR.
AG as viewed in the United  
States and europe
Effective therapeutic and pharmacological strategies depend 
on the choice of a correct target; therefore, discussing current 
different views of the concept of AG may be relevant for the 
pharmacological discussion that will follow.
Psychiatrists in the United States, and many others 
  worldwide, consider PAs as the organizing psychopathologi-
cal phenomena of panic-agoraphobic disease. Unexpected 
PAs are the “primum movens” that induce a defensive 
reaction by patients with the development of anticipatory 
anxiety and AG.4,10 In this view, “true” AG is the direct 
consequence of PAs, although its severity depends on several 
aspecific individual factors (eg, temperament) that influence 
the adaptive reactions of an individual to PAs, as well as to 
any other threatening condition. On the other hand, many 
European psychiatrists embrace the idea that agoraphobic 
attitude precedes the development of PAs and panic disorder 
(PD); thus, a specific temperament is needed for the develop-
ment of PD or for the development of AG without previous 
unexpected PAs. Studies on clinical population strongly 
support the “American view,” while epidemiological studies 
on general population seem to support the “European view.” 
The authors’ impression is that, once again, the main prob-
lem is the lack of a clear definition of the concept, and it is 
probable that these two views refer to qualitatively different 
concepts. The critical point of difference may be related to the 
meaning of negative symptoms experienced in agoraphobic 
environments: the American view considers them as the 
expression of panic vulnerability, while the European view 
includes them as part of the physiological anxiety reaction. 
A detailed discussion of the concept of AG goes beyond the 
aim of this article, but for more information there are some 
excellent publications available.8,9,11
If the American view is accepted, pharmacological treat-
ment of AG mainly relies on the blockade of PAs and on 
the facilitation of the extinction processes. If the European 
view is accepted, drug treatment of AG should focus on the 
modification of phobic temperament.
Agoraphobic behaviors  
and medical illnesses
Another open question is the classification and definition 
of patients with agoraphobic-like conditions who have 
concerns regarding incapacitation because of a medical 
condition, or fear of embarrassment because of unpredict-
able medical symptoms, but who fail to report panic-like 
symptoms.
Several medical conditions such as cardiovascular or 
respiratory diseases are associated with persistent worry 
about the occurrence of physical symptoms in different 
situations of daily life, resulting in anticipatory anxiety, 
which patients try to reduce by avoiding the feared situa-
tions or through seeking reassurance.12 In clinical practice, 
patients with heart failure or dyspnea crises are often afraid 
of staying in situations where help may not be available or 
where they have experienced clinical symptoms. This may 
in turn lead to heightened physiological arousal, to a more 
intense and generalized perception of physical signals, with 
catastrophic interpretations of harmless body sensations, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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resulting in anxiety symptoms and avoidant behaviors. 
Functional gastrointestinal disorders such as irritable bowel 
syndrome13 are associated with severe AG in patients with 
PD, but they may also induce avoidant behaviors without 
the   co-occurrence of PD. Despite their potential clinical 
relevance, these agoraphobic-like conditions are often 
underestimated in clinical settings; the patients seek help 
mainly for physical symptoms, often not drawing attention 
to their phobic avoidance; and psychiatrists or psycholo-
gists rarely get to treat them. Consequently, research studies 
on these conditions – investigating potential pathogenetic 
mechanisms, relationships with other phobic syndromes, 
and treatment strategies – are lacking.
Putative mechanisms underlying the 
development of agoraphobic behaviors
Fear conditioning and emotional learning in AG
Several studies have investigated the neurobiology of PAs, 
PD, and PD with AG, whereas AG either as a syndrome 
or as a distinct disorder has rarely been studied. Given the 
mentioned difficulties in defining AG, even data available 
using DSM criteria suggest that the pathophysiology of AG 
is not well understood and the brain areas associated with this 
condition have not yet been consistently identified. Moreover, 
no longitudinal studies are available in high-risk samples; 
thus, it is difficult to understand if abnormalities found are 
the consequence of the disorder or if they perhaps play an 
etiopathogenetic role.
Fear conditioning and emotional-learning processes are 
implicated in AG. Exposure to recurrent unexpected PAs 
may cause conditioning of fear to exteroceptive and intero-
ceptive cues present during PAs, with the development of 
defensive behaviors leading to agoraphobic avoidance and 
anticipatory anxiety. Over time, via learning mechanisms of 
stimulus generalization, fear conditioning may extend to a 
range of stimuli resembling the original conditioned stimuli 
co-occurring with panic, worsening avoidance behaviors, 
and anxious anticipation of panic (the American view). 
Alternatively, agoraphobics may have a hypersensitive fear-
conditioning system that may facilitate triggering of PAs 
(the European view).
Unfortunately, all studies are based on the American 
view. Recent studies applying experimental condition-
ing paradigms found patients with PD, compared with 
healthy controls, had an enhanced resistance to extinction 
learning of aversive conditioned responses,14 a stronger 
proclivity toward fear-conditioned overgeneralization,15 
and elevated fear responding to learned safety cues with 
slower acquisition in safety learning.16 Although these stud-
ies were not specifically focused on comparisons between 
patients with or without AG, their results support the idea 
that fear-learning processes and compromised capacity for 
inhibiting fear responses in safe contexts may be implicated in 
phobic avoidance in PD.17 Finally, a blunted fear-potentiated 
startle response to imagery of PA situations was observed 
in patients with PD and the most severe AG, compared with 
patients without or with only moderate AG, suggesting a 
compromised underlying fear-defense brain circuitry in the 
condition of chronic hyperarousal related to broad condi-
tioned avoidance and high anticipatory anxiety.18 It is not 
clear if these findings are the consequence of the disorder 
or if they precede it, since no longitudinal high-risk studies 
are available.
Neuroanatomical studies support the role of emotional 
learning processes in the development of fear responses. 
Indeed, this processes a highly complex mechanism that 
mainly involves the amygdala, with its projections to brain 
regions mediating the autonomic, endocrine, and behavioral 
components of the fear responses, and the ventromedial pre-
frontal cortex, exerting an inhibitory modulation on amygdala 
activation; however, it also implicates multiple interconnected 
neural pathways modulating attention, appraisal, safety/threat 
discrimination, and emotion regulation processes that interact 
with fear learning to influence the fear response.17,19–22
These pathways also seem to be involved in AG. In a recent 
single pilot functional magnetic resonance imaging study by 
Wittmann et al,20 researchers investigated neural mechanisms 
of AG and anticipatory anxiety in a small sample of patients 
with PD and AG using AG-specific stimuli (ie, pictures of ago-
raphobic situations). The study showed a significant activation 
in the parahippocampal cortex, the precuneus, and the insula 
during presentation of the AG-specific pictures, suggesting an 
involvement of higher spatial and visual processing, activa-
tion of autobiographical memory and self-referential aspects, 
and monitoring of internal physical sensations during induced 
agoraphobic anxiety; in addition, an increased activation of 
the amygdala and the inferior frontal cortex/insula in anxious 
anticipation of agoraphobic stimuli was found. Although this 
study is preliminary and control groups are missing, these 
findings support a potential connection between agoraphobic 
anxiety and the activations of several brain areas involved in 
perceptual and fear-learning processes.
Given the role of the mentioned brain structures in the 
modulation of agoraphobic behaviors, manipulating neu-
rotransmitters’ systems that are involved in their activation 
and de-activation could play a part in the treatment of AG. Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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The serotonergic system may have an inhibitory action on 
the locus coeruleus and amygdala, it may reduce the hypo-
thalamic release of corticotrophin-releasing factor, and it may 
inhibit one-way escape in the midbrain periaqueductal gray,23 
thus modulating behavioral and physiological responses to 
fear or stressful stimuli. The noradrenergic system seems 
to modulate autonomic arousal and behavioral activation in 
response to threatening stimuli and stressful situations, while 
the release of dopamine in the prefrontal cortex and limbic 
regions may be involved in fear-conditioning processes and 
in the acquisition of conditioned fear behaviors in animal 
models.24 Consolidation of fear memory and fear extinction 
appear to be modulated by activity of the glutamatergic 
N-methyl-D-aspartate receptors (NMDARs) in the amygdala 
and limbic regions.21 Accordingly, antagonists of NMDARs 
impair fear acquisition and extinction if administered shortly 
before a conditioning session or after extinction training;25 
the partial NMDAR agonist D-cycloserine (DCS), a novel 
compound that has been investigated in AG with PD, may 
facilitate fear extinction during exposure therapy either 
by enhancing NMDAR function during extinction or by 
reducing NMDAR function during consolidation of fear 
memory.26 Finally, the gamma-aminobutyric acid (GABA) 
system may inhibit neuronal activation and excessive output 
within limbic structures and fear circuits, facilitating fear 
extinction.27
Balance, visuospatial systems, and AG
In the last years, several studies in patients with PD and 
AG found subclinical abnormalities of their balance system 
function that seem to influence the severity of AG and may 
contribute to their symptoms of dizziness and discomfort in 
complex sensorial environments (eg, shopping malls, traffic, 
crowds).28,29 The balance control of many patients with PD 
and AG appears to rely mainly on nonvestibular, proprio-
ceptive, or mostly visual (visual dependence) cues;30 recent 
preliminary results from the authors’ team showed a higher 
balance system reactivity to peripheral visual stimulation in 
patients with PD and AG, possibly linked to a more active 
“visual alarm system”, involving visual, vestibular, and   
limbic areas, that may influence the development of AG 
in situations where environmental stimuli are   uncertain.31 
Overall, a “balance vulnerability” to AG may exist, and 
small postural modifications or sensorial stimuli from the 
surrounding environment may play a part in triggering 
situational anxiety/panic. Similarly, patients with phobic 
postural vertigo, a syndrome characterized by dizziness and 
autonomic/anxiety responses in standing or walking without 
specific vestibular diseases, often show AG-like behaviours,32 
suggesting that high sensitivity to environmental conditions 
may also lead to phobic avoidance without PD.
Finally, patients with AG and PD showed visuospatial 
cognition biases, with scarce ability of spatial orientation 
and spatial navigation and visual memory deficits, possibly 
related to distortion of the representational mechanism of 
extrapersonal space;33 it has been proposed that an over-
projection of the representation of the near space immedi-
ately surrounding the body (peripersonal space) has a role 
in claustrophobic fear.34
Patients with PD and AG also showed high sensitivity to 
environmental light or bright stimuli, having photophobic 
behavior,35 abnormal retinal light responses, and pupillary 
reflex dysfunctions, possibly linked to serotonergic and/or 
dopaminergic function.36 Moreover, since a relationship 
between photosensitivity and migraine exists,37 and a high 
comorbidity of PD with AG and migraine was found,38 
a broader dysfunction of autonomic and/or serotonergic 
systems may link photosensitivity, migraine, PAs, and 
AG.39 Overall, the findings of high sensitivity of patients 
with PD and AG to several stimuli in the surrounding 
environment support the idea that agoraphobic conditions 
may involve the activation of complex systems, beyond 
the simple fear of the recurrence of PAs, including emo-
tional responses to destabilizing/unpleasant environmental 
situations and operant-learning processes related to the 
avoidance of physical experiences provoking discomfort 
in everyday life.
Treatments for AG
Until now, clinical studies, and consequently the current 
guidelines, have been focused on therapy for AG with 
PD, whereas studies on AG without PAs are lacking. Both 
pharmacological treatments with drugs acting on different 
neurotransmitters and cognitive behavioral therapy (CBT) 
may be effective in PD with AG. The debate is ongoing as to 
whether these treatments are equally effective and whether 
combined treatments provide additional benefits; recently, 
preliminary evidence has been reported of a better efficacy 
of combined therapy than antidepressants or psychotherapy 
alone in acute-phase treatment and some superiority of 
antidepressants as compared with CBT after 9 months of 
treatment.40 Overall, the main current guidelines state that 
at present it is not possible to ascertain which of these treat-
ment modalities is more effective in PD with AG, and specific 
criteria for choosing medication, CBT, or combined therapy 
are not available.41 The efficacy of CBT in AG with PD is Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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thought to be explained by an activation and modification 
of relevant fear-learning processes via habituation and/or 
extinction and/or examining dysfunctional beliefs; however, 
30%–40% of patients do not achieve significant improvement 
with CBT alone,42 making room for a potential utility of 
pharmacological interventions for this behavioral condition. 
Even though the mechanisms of action of the existing drugs 
with antipanic and antiphobic properties remain unclear, the 
utility of these drugs may be mediated by their effects on 
several brain pathways potentially involved in pathophysiol-
ogy of AG with PD.
Medications acting on neurotransmitters appeared to 
obtain comparable rates of clinical remission for both PAs 
and agoraphobic avoidance in patients with PD and AG, 
while the probability of relapses during long-term phar-
macological treatment seems to be lower for AG than for 
PAs.43 Nevertheless, in a study by van Apeldoorn et al,44 
between 20% and 40% of patients with PD and AG did 
not fully respond to adequate pharmacotherapy alone or, 
similarly, to CBT administered alone, and so far the combi-
nation of CBT and pharmacotherapy does not appear to fill 
this gap. In addition, 25%–50% of patients relapse within 
6 months after drug discontinuation and up to 40%–50% 
of patients still have residual panic-phobic symptoms after 
3–6 years.45 Finally, it is still unclear to what extent the 
pharmacological remission of both full and limited-symptom 
spontaneous PAs may indirectly influence the remission of 
AG in patients with AG and PD, or to what extent a specific 
drug effect on phobic conditions is necessary to obtain a 
complete remission.
Aim of the study
Given the relevance of AG to the general population and the 
tendency of AG to become chronic, looking for effective treat-
ments is important. To reach this goal, the authors will summa-
rize and discuss recent evidence regarding the pharmacological 
treatment of AG, based on clinical trials available from 2000 
to June 2011, discuss factors that might affect the validity of 
the studies, and, finally, suggest putative mechanisms that may 
be involved in the development of new drugs.
Methods
A scientific literature search was performed using MED-
LINE, EBSCO, and Cochrane databases, with keywords 
individuated by MeSH research. These keywords included 
(AG OR “panic disorder”) AND (“drug therapy” OR pharma-
cotherapy) AND behavior*; NOT (“depressive disorder” OR 
“mood disorder”); NOT (“psychotic disorder”). The syntax 
respected instruction information described in the databases. 
Citation searches were also conducted manually.
All studies were analyzed applying the following inclu-
sion criteria:
•	 English-language articles
•	 Clinical trials
•	 Blinded studies
•	 Studies published after 2000
•	 Studies where psychopathological diagnosis was per-
formed using DSM criteria, ICD-10 criteria, or an exact 
description of the disorder and duration of symptoms
•	 Clinical outcomes had to be scored by a standardized 
psychometric scale, by self-report, by observer-rated 
measures, by behavior test, or by a numeric rating index 
of anxiety and/or agoraphobic symptoms (eg, avoidance, 
anticipatory anxiety, and anxiety state)
•	 For the groups in the studies, each drug to be adminis-
trated without other drugs that can influence or interact 
with treatment.
For the selection of articles, exclusion criteria were:
•	 Trials not randomized controlled and without control 
group
•	 Case reports
•	 Studies where population’s diagnosis was PD without AG
•	 Studies where AG was in comorbidity with other psy-
chopathologies or neurological pathologies
•	 Studies with a pediatric population.
After selection, articles were divided on the basis of 
the pharmacological classes. After this subdivision, in each 
article the following parameters were identified and described:   
(1) characteristics of the studies; (2) drug therapies and doses; 
(3) duration of treatments; (4) control group(s); (5) outcome 
measures of agoraphobic symptoms and/or panic/anxiety; (6) 
timing of follow-up; and (7) results. When available, specific 
psychometric measures of AG were reported and highlighted; 
when these were lacking, global scores of psychometric scales 
that include evaluation of AG severity, such as the Panic and 
Agoraphobia Scale, the Panic Attack Symptoms Scale, or the 
Panic Disorder Severity Scale, were reported.
Results
The electronic search identified 235 articles. Among these, 
210 were excluded and 25 studies were selected (Figure 1). 
No studies were found that focused on AG without PD, and 
all the selected studies included patients with AG and PD. 
Pharmacological classes used in the selected clinical trials 
are summarized in Table 1. Details of the selected studies 
are outlined in Table 2.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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44 36 57 22 10 11 30
Non-English
language
Review and
meta-
analysis
Comorbidity No clinical
trials
– No anxiety
measure 
– No diagnosis
of AG
– Involving of
other anxiety
disorders 
– Other aims 
More drugs
therapy
– No control
group 
– No blinded
studies
235 161 205 125 68 46 36 25
Figure 1 Selection of articles.
Abbreviation: AG, agoraphobia.
Table 1 Number of articles selected for each pharmacological class
Pharmacological class Articles (n)
TCAs 5
MAOis 1
BDZs 3
SSRis 8
NARis 2
SNRis 1
Other
  Gabapentin (GABAergic anticonvulsant) 1
  inositol (natural isomer of glucose) 1
  DCS (partial agonist of the NMDARs) 2
    Pagoclone (partial agonist at the  
GABA-A/BDZ receptor)
1
Abbreviations:  BDZ,  benzodiazepine;  DCS,  D-cycloserine;  GABA,  gamma-
aminobutyric acid; MAOi, monoamine oxidase inhibitor; NARi, selective noradrenergic 
reuptake  inhibitor;  NMDAR,  N-methyl-D-aspartate  receptor;  SNRi,  serotonin-
norepinephrine  reuptake  inhibitor;  SSRi,  selective  serotonin  reuptake  inhibitor; 
TCA, tricyclic antidepressant.
Discussion
This review of randomized, controlled pharmacological trials 
on AG published over the last 11 years underscores the diffi-
culties in identifying psychotropic drugs that may specifically 
improve AG. Many reasons may explain these difficulties. 
Since the few studies that included patients with AG and 
panic-like symptoms (but without full-blown PD) had many 
methodological shortcomings (eg, lack of randomization 
or control groups), they were excluded from this review; 
therefore, no specific data on “not panic” agoraphobics are 
available. All the studies reported in this article included 
patients with AG associated with PD, as per DSM criteria, 
and so disentangling the specific effects of AG is difficult.
The authors begin by discussing the putative limitations of 
the studies included. Many studies on PD with AG reported 
outcome measures evaluating only the global improvement 
of the clinical condition, without highlighting potential dif-
ferences in drug effects on distinct clinical phenomena such 
as frequency of PAs, anticipatory anxiety, phobic avoidance, 
and their interaction. Moreover, some methodological issues 
may influence the results of the included studies. Several 
studies did not report effect size analysis in their results, 
thus decreasing the strength of their conclusions. The sample 
sizes were often small and some studies included patients 
with other psychiatric disorders in comorbidity with PD 
and AG, thus possibly affecting the external validity of the 
results and/or masking potential significant effects of the 
treatments. Some data arose from pharmaceutical studies 
that might have had different settings than spontaneous 
clinical studies, thus affecting the comparisons of the results. 
In a few comparative clinical trials, the placebo group was 
missing,48,52,57,60,62,63,68 even though the comparator drugs were 
well-known, effective antipanic drugs. Two studies60,62 were 
single-blinded (eg, the investigator rating psychometric scales 
did not know which treatment was administered, whereas the 
patients did), thus patients’ expectance of treatment efficacy 
cannot be excluded as an influence. Finally, all studies but 
two44,45 considered short-term outcomes, not allowing for 
conclusions regarding maintenance properties and long-term 
effects of the tested drugs.
Keeping these limitations in mind, the authors found that 
selective serotonin reuptake inhibitors (SSRIs) and tricyclic 
antidepressants (TCAs) are the most studied drugs in AG Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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with PD, according to previous reviews.12,23 Among SSRIs, 
paroxetine is the most used drug in the selected clinical 
trials,48,54–57,60,62,63 showing high efficacy on both panic and 
phobic symptoms, and also when severity of AG is measured 
by specific psychometric scales. The comparison between 
CBT and paroxetine suggests their similar efficacy on agora-
phobic behaviors but with some superiority of paroxetine on 
PAs in the acute phases of the treatment;55 finally, the addition 
of paroxetine to CBT in patients that did not respond to CBT 
alone is significantly more effective in improving agorapho-
bic behaviors than the addition of placebo.54
Overall these data indicate the utility of paroxetine as 
a pharmacological augmentation strategy in patients with 
AG who do not fully respond to CBT sessions and they 
underscore its efficacy on PAs. Since the recurrence of PAs 
worsen agoraphobic behaviors in PD and interfere with the 
remission of AG, the efficacy of paroxetine on AG may also 
be linked to its antipanic properties; thus, treatment with 
paroxetine in patients with AG and a high recurrence of PAs 
may be more appropriate than CBT alone. Sertraline,48,57 
citalopram,58–60 and escitalopram58,59 also appear to be effec-
tive in PD with AG, whereas fluvoxamine48,68 shows less 
consistent efficacy, at least on PAs and global panic-phobic 
psychometric   measures. Although showing a suppressive 
effect on spontaneous PAs, fluoxetine53 does not appear to 
be effective on situational PAs compared with placebo, and 
its efficacy on AG measures is limited; these findings are 
similar to those in a study on imipramine performed before 
2000,71 supporting the idea that antidepressants may not have 
a similar effect on all aspects of PD with AG. Among TCAs, 
which are less tolerable and safe than SSRIs, clomipramine 
shows an efficacy on both panic and phobic symptoms similar 
to paroxetine and sertraline,48 whereas imipramine shows 
mixed results; indeed, although imipramine is more effec-
tive than placebo in long-term maintenance,44 it appears to 
be less effective than sertraline on short-term outcomes,48 as 
measured by global panic-phobic psychometric scales, and a 
combined therapy with CBT plus imipramine does not offer 
significant benefits on agoraphobic symptoms compared with 
CBT plus placebo.46
Benzodiazepines (BDZs), such as clonazepam50,51 and 
alprazolam52 are effective in AG with PD and the association 
of alprazolam to antidepressant in the first weeks of therapy 
may accelerate the reduction of global anxiety,52 whereas 
the only study on pagoclone,64 a partial agonist of GABA-A 
BDZ receptors, shows inconsistent results. However, the use 
of BDZs is recommended with caution, because of risk of 
tolerance, dependence, and withdrawal symptoms;70   moreover, 
patients receiving combined therapy with CBT and BDZs who 
subsequently discontinue BDZ treatment experience a loss 
of efficacy compared with CBT and placebo, possibly due to 
interference of BDZs with fear-extinction processes.70
Among other pharmacological classes, venlafaxine63 
appears to be effective on both panic and phobic symptoms; 
the only study with inositol68 supports the effectiveness in AG 
with PD emerging from previous clinical trials,71,72 but more 
studies are needed before drawing definitive   conclusions. 
Reboxetine61 appears to be effective on both panic and phobic 
symptoms compared with placebo, while when compared 
with paroxetine62 it shows a similar efficacy on phobic avoid-
ance and anticipatory anxiety but a lower efficacy on PAs; 
these data support the role of the noradrenergic system in 
modulation of avoidance behaviors but underscore the rel-
evance of acting on the serotonergic system to decrease the 
PAs. Finally, gabapentin64 does not show different efficacy 
than placebo and moclobemide49 does not decrease phobic 
avoidance compared with placebo, even though it does show 
some efficacy on PAs.
As previously discussed, despite these pharmacological 
therapeutic options available for PD with AG, they do not 
seem to be able to achieve a full remission in all treated 
patients either when administered alone or in association with 
CBT.67 Beyond the discussed absence of a widely accepted 
definition, this critical issue may be partly related to the patho-
genetic complexity of AG, which is not usually taken into 
account in clinical trials. A preliminary open study showed 
that citalopram influences the balance system in patients with 
PD and AG by improving their postural stability, as measured 
by static posturography, especially when visual information 
is lacking; in addition, patients whose posturography scores 
were highly abnormal at the end of the trial were still agora-
phobic, whereas most patients whose balance system func-
tion improved were no longer agoraphobic, underscoring the 
involvement of balance system dysfunction in PD with AG 
and the relevance of the serotonergic system in connections 
between balance and AG.73 Further studies are warranted to 
investigate the possible role of unrecognized balance dysfunc-
tions in patients with PD and AG who do not fully respond to 
treatments and to study appropriate interventions.
A reanalysis of pooled samples of patients from previ-
ous homogeneous pharmacological studies performed by 
the authors’ team showed a higher efficacy of sertraline and 
clomipramine than paroxetine, fluvoxamine, and citalo-
pram on agoraphobic symptoms (unpublished data). This 
finding may be related to their additional ability to modu-
late the dopaminergic system, besides their main effect on Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Systematic analysis of selected studies
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
TCAs Mavissakalian  
and Perel45
Double-blind, crossover design
Aim: to test the effects of  
imipramine maintenance  
therapy in a second-year  
extension of a previous study
imipramine  
(2.25 mg/kg/day)
Maintenance of imipramine  
therapy (1 year) in patients  
who had taken imipramine for  
a year before this study, after  
stable remission obtained by 
6-month imipramine acute-phase   
treatment
1.   Maintenance of placebo condition  
(1 year) in patients who had taken  
placebo for a year before this study,  
after stable remission obtained by  
6-month imipramine acute-phase  
treatment
2.   Placebo substitution (1 year) in  
patients who had taken imipramine  
for a year before this study, after  
stable remission obtained by 6-month  
imipramine acute-phase treatment
AG subscale of FQ 
individualized clinical measure  
of phobic anxiety and avoidance  
(9-point scale) 
Functional in vivo measure  
of phobic anxiety derived from  
a behavioral assessment  
(9-point scale) 
Number and severity of PAs
1 year Significant effect of imipramine in 
maintenance remission
Mavissakalian  
and Perel46
Reanalysis of results from  
previous studies
Aim: to explore relationship  
between duration of  
imipramine therapy and relapse
imipramine  
(2.25 mg/kg/day)
6 months of imipramine therapy 12–14, 18, or 30 months  
of imipramine therapy
AG subscale of FQ 
individualized clinical measure  
of phobic anxiety and avoidance  
(9-point scale) 
Functional in vivo measure  
of phobic anxiety derived from  
a behavioral assessment  
(9-point scale) 
Number and severity of PAs
ND No difference in relapse rate in the different 
groups 
Patients who relapsed showed lower severity 
of agoraphobic symptoms than pretreatment 
phase, whereas number of PAs measured at 
relapse and pretreatment phase did not differ
Marchand  
et al47
Double-blind, randomized,  
placebo-controlled trial
imipramine (25–200 mg/day) +  
CBT groups (cognitive  
and exposure or cognitive  
or exposure or supportive  
therapy)
22 weeks, including 4 weeks  
before beginning of CBT and  
18 weeks during CBT
Placebo + CBT treatment groups  
(cognitive and exposure or cognitive  
or exposure or supportive therapy)
ACQ 
Mi-A 
Mi-PF
week 22 
3, 6, 12  
months post  
treatment
At week 22, anxiety and agoraphobic 
symptoms significantly decreased in 
imipramine and placebo groups without 
differences between groups; after 12 months 
no significant differences were detected 
within and between groups 
in imipramine group, the proportion of 
panic-free patients post treatment and 
at 12 months did not differ among CBT 
treatments; in placebo group these data were 
not shown
Bandelow  
et al48
Double-blind, randomized,  
placebo-controlled trial
Clomipramine  
(max 112.5 mg/day)
10 weeks 1. Placebo 
2. exercise (running)
P&A total scores and subscales,  
including avoidance and  
anticipatory anxiety subscales 
BAi 
FQ
ND Both exercise and clomipramine led to a 
significant global improvement in comparison 
with placebo 
Overall, clomipramine was significantly more 
effective and faster in improving anxiety, 
panic, and phobic symptoms than exercise; 
however, exercise exerted its effect mainly 
reducing anticipatory anxiety and panic-
related disability and the decrease of FQ 
scores in exercise group was higher than 
placebo group and similar to clomipramine 
group
Perna et al49 Double-blind, randomized,  
controlled trial
Clomipramine  
(max 50 mg/day)
30 days 1. imipramine (max 50 mg/day) 
2. Paroxetine (10 mg/day) 
3. Sertraline (25 mg/day) 
4. Fluvoxamine (50 mg/day)
PASS 
FQ
30 days FQ scores decreased significantly in all 
treatment groups 
PASS scores decreased significantly in all but 
the fluvoxamine treatment group 
Sertraline was more effective than 
imipramine in improving PASS scores
MAOis Uhlenhuth  
et al50
Multicenter, double-blind,  
randomized, placebo- 
controlled trial
Moclobemide (75, 150, 300,  
600, or 900 mg/day)
8 weeks Placebo Agoraphobic avoidance and  
anticipatory anxiety – CGi  
11-point scale of fear and 5-point  
scale of avoidance for main phobic  
situations or activities 
Unexpected and situational PAs  
(daily diary)
weeks 1, 2, 3,  
4, 6, 8
Moclobemide significantly improved both 
unexpected and situational PAs (systematic 
dose-related effect), whereas it did not show 
significant difference to placebo in fear and 
phobic avoidance
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Table 2 Systematic analysis of selected studies
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
TCAs Mavissakalian  
and Perel45
Double-blind, crossover design
Aim: to test the effects of  
imipramine maintenance  
therapy in a second-year  
extension of a previous study
imipramine  
(2.25 mg/kg/day)
Maintenance of imipramine  
therapy (1 year) in patients  
who had taken imipramine for  
a year before this study, after  
stable remission obtained by 
6-month imipramine acute-phase   
treatment
1.   Maintenance of placebo condition  
(1 year) in patients who had taken  
placebo for a year before this study,  
after stable remission obtained by  
6-month imipramine acute-phase  
treatment
2.   Placebo substitution (1 year) in  
patients who had taken imipramine  
for a year before this study, after  
stable remission obtained by 6-month  
imipramine acute-phase treatment
AG subscale of FQ 
individualized clinical measure  
of phobic anxiety and avoidance  
(9-point scale) 
Functional in vivo measure  
of phobic anxiety derived from  
a behavioral assessment  
(9-point scale) 
Number and severity of PAs
1 year Significant effect of imipramine in 
maintenance remission
Mavissakalian  
and Perel46
Reanalysis of results from  
previous studies
Aim: to explore relationship  
between duration of  
imipramine therapy and relapse
imipramine  
(2.25 mg/kg/day)
6 months of imipramine therapy 12–14, 18, or 30 months  
of imipramine therapy
AG subscale of FQ 
individualized clinical measure  
of phobic anxiety and avoidance  
(9-point scale) 
Functional in vivo measure  
of phobic anxiety derived from  
a behavioral assessment  
(9-point scale) 
Number and severity of PAs
ND No difference in relapse rate in the different 
groups 
Patients who relapsed showed lower severity 
of agoraphobic symptoms than pretreatment 
phase, whereas number of PAs measured at 
relapse and pretreatment phase did not differ
Marchand  
et al47
Double-blind, randomized,  
placebo-controlled trial
imipramine (25–200 mg/day) +  
CBT groups (cognitive  
and exposure or cognitive  
or exposure or supportive  
therapy)
22 weeks, including 4 weeks  
before beginning of CBT and  
18 weeks during CBT
Placebo + CBT treatment groups  
(cognitive and exposure or cognitive  
or exposure or supportive therapy)
ACQ 
Mi-A 
Mi-PF
week 22 
3, 6, 12  
months post  
treatment
At week 22, anxiety and agoraphobic 
symptoms significantly decreased in 
imipramine and placebo groups without 
differences between groups; after 12 months 
no significant differences were detected 
within and between groups 
in imipramine group, the proportion of 
panic-free patients post treatment and 
at 12 months did not differ among CBT 
treatments; in placebo group these data were 
not shown
Bandelow  
et al48
Double-blind, randomized,  
placebo-controlled trial
Clomipramine  
(max 112.5 mg/day)
10 weeks 1. Placebo 
2. exercise (running)
P&A total scores and subscales,  
including avoidance and  
anticipatory anxiety subscales 
BAi 
FQ
ND Both exercise and clomipramine led to a 
significant global improvement in comparison 
with placebo 
Overall, clomipramine was significantly more 
effective and faster in improving anxiety, 
panic, and phobic symptoms than exercise; 
however, exercise exerted its effect mainly 
reducing anticipatory anxiety and panic-
related disability and the decrease of FQ 
scores in exercise group was higher than 
placebo group and similar to clomipramine 
group
Perna et al49 Double-blind, randomized,  
controlled trial
Clomipramine  
(max 50 mg/day)
30 days 1. imipramine (max 50 mg/day) 
2. Paroxetine (10 mg/day) 
3. Sertraline (25 mg/day) 
4. Fluvoxamine (50 mg/day)
PASS 
FQ
30 days FQ scores decreased significantly in all 
treatment groups 
PASS scores decreased significantly in all but 
the fluvoxamine treatment group 
Sertraline was more effective than 
imipramine in improving PASS scores
MAOis Uhlenhuth  
et al50
Multicenter, double-blind,  
randomized, placebo- 
controlled trial
Moclobemide (75, 150, 300,  
600, or 900 mg/day)
8 weeks Placebo Agoraphobic avoidance and  
anticipatory anxiety – CGi  
11-point scale of fear and 5-point  
scale of avoidance for main phobic  
situations or activities 
Unexpected and situational PAs  
(daily diary)
weeks 1, 2, 3,  
4, 6, 8
Moclobemide significantly improved both 
unexpected and situational PAs (systematic 
dose-related effect), whereas it did not show 
significant difference to placebo in fear and 
phobic avoidance
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
BDZs valença  
et al51
Double-blind, randomized,  
placebo-controlled trial
Clonazepam (2 mg/day) 6 weeks Placebo PASS 
HAM-A 
CGi
week 6 Clonazepam showed significant reduction of 
anticipatory anxiety, phobic avoidance, PAs, 
global anxiety, and CGi scores compared 
with placebo
valença  
et al52
Randomized, placebo- 
controlled trial
Clonazepam (2 mg/day) 6 weeks Placebo GPi for PD 
Number of PAs 
HAM-A
weeks 2, 6 in clonazepam group, by end of week 6 there 
was a statistically significant remission of PAs 
and decrease in anxiety
Katzelnick  
et al53
Multicenter, naturalistic,  
randomized study
Alprazolam
(0.25 to .5 mg/day) +  
SSRis/SNRis
8 weeks (including 3- to 4-week  
taper of alprazolam)
SSRis/SNRis alone Number of PAs 
HAM-A 
GPi 
CGi-i
weeks 1, 2, 3,  
4, 5, 6, 7, 8
Combined therapy showed an earlier onset 
of effect on anxiety and global improvement 
measures than SSRis/SNRls alone 
PAs decreased significantly at week 8 in 
both groups without differences between 
treatment groups at any time point
SSRis Uhlenhuth  
et al54
Multicenter, double-blind,  
randomized, placebo- 
controlled trial
Fluoxetine (one group  
10 mg/day; one group  
20 mg/day)
10 weeks Placebo index of AG (0- to 8-point scale) 
Number of spontaneous and  
situational PAs (daily diary)
weeks 1, 2, 4,  
6, 8, 10
Fluoxetine showed a statistically significant, 
dose-dependent suppressive effect on 
spontaneous PAs, whereas there were no 
significant drug effects on situational PAs 
A therapeutic effect of fluoxetine on AG was 
found only at the lower dose
Kampman  
et al55
Double-blind, randomized,  
placebo-controlled trial
Patients unsuccessfully treated  
with initial manual-guided CBT  
alone (15 sessions)
Paroxetine (to	40 mg/day) +  
CBT
8 weeks Placebo + CBT ACQ 
Mi-A (total score, Mi-A and  
Mi-PF subscales) 
ADS
week 8 Patients in paroxetine + CBT condition 
significantly improved on agoraphobic 
behaviors and anxiety discomfort 
Trend showed more panic-free patients in 
CBT + paroxetine group
Hendriks  
et al56
Randomized, controlled trial
Patients aged 60 years and  
older
Paroxetine (to 40 mg/day) 26 weeks 1. CBT 
2. 14-week wL
ACQ 
Mi-A 
Proportion of patients free  
from PAs (panic-free ratio)
weeks 8, 14  
(conclusion  
CBT/wL),  
26 (treated  
patients only)
Compared with the wL, the 8- and 14-week 
ACQ and MI-A scores had significantly 
improved for both the paroxetine and the 
CBT conditions; the improvements were 
sustained at the 26-week follow-up without 
differences between groups 
The baseline-to-14 weeks panic-free ratio 
in the paroxetine condition had increased 
significantly, an improvement that was 
sustained at week 26 
Although not statistically significant, in the 
CBT condition, the baseline-to-14 weeks 
ratio had risen and had improved further at 
follow-up (statistical trend) 
The panic-free ratio for the wL showed no 
changes over time
wedekind  
et al57
Double-blind, randomized,  
placebo-controlled trial
Paroxetine (10–40 mg/day) +  
relaxation training or aerobic  
exercise
10 weeks Placebo + relaxation training  
or aerobic exercise
P&A 
HAM-A 
BAi 
CGi
weeks 1, 2, 4,  
6, 8, 10
P&A, CGi, and BAi scores decreased 
significantly in all treatment groups over 
time, but paroxetine-treated patients were 
significantly more improved than placebo-
treated patients 
On the CGi, patients in the exercise groups 
(+ paroxetine or placebo) had a trend 
toward better improvement compared with 
relaxation 
HAM-A scores decreased significantly, 
without differences, in all treatment groups
Bandelow  
et al58
Double-blind, randomized,
controlled trial
Sertraline (50–150 mg/day) 12 weeks Paroxetine (40–60 mg/day) P&A 
Frequency and intensity of PAs  
and anticipatory anxiety  
(panic diary)
weeks 1, 2, 4,  
6, 8, 12
Sertraline and paroxetine showed equivalent 
efficacy 
Sertraline was significantly better tolerated  
and was associated with significantly less  
clinical worsening during taper than paroxetine
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
BDZs valença  
et al51
Double-blind, randomized,  
placebo-controlled trial
Clonazepam (2 mg/day) 6 weeks Placebo PASS 
HAM-A 
CGi
week 6 Clonazepam showed significant reduction of 
anticipatory anxiety, phobic avoidance, PAs, 
global anxiety, and CGi scores compared 
with placebo
valença  
et al52
Randomized, placebo- 
controlled trial
Clonazepam (2 mg/day) 6 weeks Placebo GPi for PD 
Number of PAs 
HAM-A
weeks 2, 6 in clonazepam group, by end of week 6 there 
was a statistically significant remission of PAs 
and decrease in anxiety
Katzelnick  
et al53
Multicenter, naturalistic,  
randomized study
Alprazolam
(0.25 to .5 mg/day) +  
SSRis/SNRis
8 weeks (including 3- to 4-week  
taper of alprazolam)
SSRis/SNRis alone Number of PAs 
HAM-A 
GPi 
CGi-i
weeks 1, 2, 3,  
4, 5, 6, 7, 8
Combined therapy showed an earlier onset 
of effect on anxiety and global improvement 
measures than SSRis/SNRls alone 
PAs decreased significantly at week 8 in 
both groups without differences between 
treatment groups at any time point
SSRis Uhlenhuth  
et al54
Multicenter, double-blind,  
randomized, placebo- 
controlled trial
Fluoxetine (one group  
10 mg/day; one group  
20 mg/day)
10 weeks Placebo index of AG (0- to 8-point scale) 
Number of spontaneous and  
situational PAs (daily diary)
weeks 1, 2, 4,  
6, 8, 10
Fluoxetine showed a statistically significant, 
dose-dependent suppressive effect on 
spontaneous PAs, whereas there were no 
significant drug effects on situational PAs 
A therapeutic effect of fluoxetine on AG was 
found only at the lower dose
Kampman  
et al55
Double-blind, randomized,  
placebo-controlled trial
Patients unsuccessfully treated  
with initial manual-guided CBT  
alone (15 sessions)
Paroxetine (to	40 mg/day) +  
CBT
8 weeks Placebo + CBT ACQ 
Mi-A (total score, Mi-A and  
Mi-PF subscales) 
ADS
week 8 Patients in paroxetine + CBT condition 
significantly improved on agoraphobic 
behaviors and anxiety discomfort 
Trend showed more panic-free patients in 
CBT + paroxetine group
Hendriks  
et al56
Randomized, controlled trial
Patients aged 60 years and  
older
Paroxetine (to 40 mg/day) 26 weeks 1. CBT 
2. 14-week wL
ACQ 
Mi-A 
Proportion of patients free  
from PAs (panic-free ratio)
weeks 8, 14  
(conclusion  
CBT/wL),  
26 (treated  
patients only)
Compared with the wL, the 8- and 14-week 
ACQ and MI-A scores had significantly 
improved for both the paroxetine and the 
CBT conditions; the improvements were 
sustained at the 26-week follow-up without 
differences between groups 
The baseline-to-14 weeks panic-free ratio 
in the paroxetine condition had increased 
significantly, an improvement that was 
sustained at week 26 
Although not statistically significant, in the 
CBT condition, the baseline-to-14 weeks 
ratio had risen and had improved further at 
follow-up (statistical trend) 
The panic-free ratio for the wL showed no 
changes over time
wedekind  
et al57
Double-blind, randomized,  
placebo-controlled trial
Paroxetine (10–40 mg/day) +  
relaxation training or aerobic  
exercise
10 weeks Placebo + relaxation training  
or aerobic exercise
P&A 
HAM-A 
BAi 
CGi
weeks 1, 2, 4,  
6, 8, 10
P&A, CGi, and BAi scores decreased 
significantly in all treatment groups over 
time, but paroxetine-treated patients were 
significantly more improved than placebo-
treated patients 
On the CGi, patients in the exercise groups 
(+ paroxetine or placebo) had a trend 
toward better improvement compared with 
relaxation 
HAM-A scores decreased significantly, 
without differences, in all treatment groups
Bandelow  
et al58
Double-blind, randomized,
controlled trial
Sertraline (50–150 mg/day) 12 weeks Paroxetine (40–60 mg/day) P&A 
Frequency and intensity of PAs  
and anticipatory anxiety  
(panic diary)
weeks 1, 2, 4,  
6, 8, 12
Sertraline and paroxetine showed equivalent 
efficacy 
Sertraline was significantly better tolerated  
and was associated with significantly less  
clinical worsening during taper than paroxetine
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
Stahl et al59 Multicenter, double-blind,  
randomized, placebo- 
controlled trial
escitalopram (5 mg/day ÷ max  
20 mg/day)
Citalopram (10 mg/day ÷ max  
40 mg/day)
10 weeks Placebo P&A 
Anticipatory anxiety and number  
of PAs (from PASS score) 
CGi-phobic avoidance 
HAM-A
weeks 1, 2, 4,  
6, 8, 10
At the endpoint, escitalopram (vs placebo) 
had significant effect on anticipatory anxiety 
and HAM-A scores 
Both escitalopram and citalopram had 
significant effect on number of PAs and 
CGi-phobic avoidance score compared 
with placebo, without significant differences 
between them
Bandelow  
et al60
Double-blind, randomized,  
placebo-controlled trial
escitalopram (5 mg/day ÷ max  
20 mg/day)
Citalopram (10 mg/day ÷ max  
40 mg/day)
10 weeks Placebo P&A (agoraphobic avoidance  
behavior, anticipatory anxiety  
and PAs subscales)
week 10 Compared with placebo, escitalopram had 
significant effect on agoraphobic avoidance 
behavior and anticipatory anxiety subscales 
and citalopram on anticipatory anxiety 
subscale 
Both drugs, compared with placebo, 
significantly decreased the number of PAs, 
without differences between them
Perna et al61 Single-blind, randomized,  
controlled trial
Citalopram (10 mg/day ÷ max  
50 mg/day)
ND Paroxetine (10 mg/day ÷ max  
50 mg/day)
PASS 
FQ
Days 7, 60 Both drugs significantly improved panic and 
phobic symptomatology 
A trend of higher efficacy of paroxetine in 
reducing PAs was found
NARis versiani  
et al62
Double-blind, randomized,  
placebo-controlled trial
Reboxetine (2–8 mg/day) 8 weeks Placebo SPAAS and number of PAs weeks 1, 2, 3,  
4, 5, 6, 7, 8
At last assessment, anticipatory anxiety, AG, 
and PAs significantly decreased in reboxetine 
group
Bertani  
et al63
Single-blind, randomized,  
controlled trial
Reboxetine (2–8 mg/day) 90 days Paroxetine (10 mg/day ÷ 40 mg/day) PASS 
FQ
Day 90 A greater effect of paroxetine than 
reboxetine on PAs was found, while no 
differences for anticipatory anxiety and 
phobic avoidance were found
SNRis Pollack et al64 Double-blind, randomized,  
controlled trial
venlafaxine extended release  
(75 or 150 mg/day)
12 weeks 1. Placebo 
2. Paroxetine (40 mg/day)
PAAS (anticipatory anxiety  
and PAs subscales) 
Phobic fear and avoidance  
of phobia scale 
HAM-A 
PDSS
weeks 1, 2, 3,  
4, 6, 8, 10, 12
venlafaxine and paroxetine showed 
significant effects on all measures, compared 
with placebo, without differences between 
them
Other Pande et al65 Double-blind, randomized,  
placebo-controlled trial
Gabapentin (600–3600 mg/day) 8 weeks Placebo P&A total score 
HAM-A
week 8 No significant reduction of anxiety and panic 
symptoms in gabapentin group compared 
with placebo 
A trend of higher efficacy in a subgroup of 
more severely ill patients was found
Sandford  
et al66
Double-blind, randomized,  
placebo-controlled, crossover  
design
Pagoclone (0.3 mg/day) 2 weeks Placebo HAM-A 
Frequency of PAs (diary)
weeks 1, 2, 3,  
4, 5, 6
Statistical trend of decrease in the number of 
PAs within pagoclone group was found, but 
no differences were found when compared 
with placebo
Otto et al67 Randomized, double- 
blind, placebo-controlled  
augmentation trial
DCS (50 mg) + CBT  
(five sessions)
Administration 1 hour  
before CBT sessions 3–5
Placebo (50 mg) + CBT (five sessions) PDSS 
CGi-S for PD (global score,  
number and frequency of PAs,  
anticipatory anxiety, phobic  
avoidance, impairment of function)
1 week (post  
treatment)  
and 1 month  
(follow-up)  
following  
cessation of  
treatment
DCS had an augmentation effect on CBT 
efficacy 
PDSS and CGI-S decreased significantly in 
DCS group (vs placebo) post treatment, 
whereas no significant differences between 
groups were shown in follow-up
Siegmund  
et al68
Double-blind, randomized,  
placebo-controlled trial
DCS (50 mg) + CBT Administration once before CBT 
exposure sessions (only weeks  
2, 3, 4)
Placebo + CBT P&A 
BAi 
HAM-A
After 11 CBT  
sessions and  
at 1 and 5  
months after  
end of CBT
Both groups profited considerably from 
therapy and DCS did not significantly 
improve the outcome 
There was a statistical trend in the more 
severely ill patients that DCS accelerated 
symptom reduction post therapy
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
Stahl et al59 Multicenter, double-blind,  
randomized, placebo- 
controlled trial
escitalopram (5 mg/day ÷ max  
20 mg/day)
Citalopram (10 mg/day ÷ max  
40 mg/day)
10 weeks Placebo P&A 
Anticipatory anxiety and number  
of PAs (from PASS score) 
CGi-phobic avoidance 
HAM-A
weeks 1, 2, 4,  
6, 8, 10
At the endpoint, escitalopram (vs placebo) 
had significant effect on anticipatory anxiety 
and HAM-A scores 
Both escitalopram and citalopram had 
significant effect on number of PAs and 
CGi-phobic avoidance score compared 
with placebo, without significant differences 
between them
Bandelow  
et al60
Double-blind, randomized,  
placebo-controlled trial
escitalopram (5 mg/day ÷ max  
20 mg/day)
Citalopram (10 mg/day ÷ max  
40 mg/day)
10 weeks Placebo P&A (agoraphobic avoidance  
behavior, anticipatory anxiety  
and PAs subscales)
week 10 Compared with placebo, escitalopram had 
significant effect on agoraphobic avoidance 
behavior and anticipatory anxiety subscales 
and citalopram on anticipatory anxiety 
subscale 
Both drugs, compared with placebo, 
significantly decreased the number of PAs, 
without differences between them
Perna et al61 Single-blind, randomized,  
controlled trial
Citalopram (10 mg/day ÷ max  
50 mg/day)
ND Paroxetine (10 mg/day ÷ max  
50 mg/day)
PASS 
FQ
Days 7, 60 Both drugs significantly improved panic and 
phobic symptomatology 
A trend of higher efficacy of paroxetine in 
reducing PAs was found
NARis versiani  
et al62
Double-blind, randomized,  
placebo-controlled trial
Reboxetine (2–8 mg/day) 8 weeks Placebo SPAAS and number of PAs weeks 1, 2, 3,  
4, 5, 6, 7, 8
At last assessment, anticipatory anxiety, AG, 
and PAs significantly decreased in reboxetine 
group
Bertani  
et al63
Single-blind, randomized,  
controlled trial
Reboxetine (2–8 mg/day) 90 days Paroxetine (10 mg/day ÷ 40 mg/day) PASS 
FQ
Day 90 A greater effect of paroxetine than 
reboxetine on PAs was found, while no 
differences for anticipatory anxiety and 
phobic avoidance were found
SNRis Pollack et al64 Double-blind, randomized,  
controlled trial
venlafaxine extended release  
(75 or 150 mg/day)
12 weeks 1. Placebo 
2. Paroxetine (40 mg/day)
PAAS (anticipatory anxiety  
and PAs subscales) 
Phobic fear and avoidance  
of phobia scale 
HAM-A 
PDSS
weeks 1, 2, 3,  
4, 6, 8, 10, 12
venlafaxine and paroxetine showed 
significant effects on all measures, compared 
with placebo, without differences between 
them
Other Pande et al65 Double-blind, randomized,  
placebo-controlled trial
Gabapentin (600–3600 mg/day) 8 weeks Placebo P&A total score 
HAM-A
week 8 No significant reduction of anxiety and panic 
symptoms in gabapentin group compared 
with placebo 
A trend of higher efficacy in a subgroup of 
more severely ill patients was found
Sandford  
et al66
Double-blind, randomized,  
placebo-controlled, crossover  
design
Pagoclone (0.3 mg/day) 2 weeks Placebo HAM-A 
Frequency of PAs (diary)
weeks 1, 2, 3,  
4, 5, 6
Statistical trend of decrease in the number of 
PAs within pagoclone group was found, but 
no differences were found when compared 
with placebo
Otto et al67 Randomized, double- 
blind, placebo-controlled  
augmentation trial
DCS (50 mg) + CBT  
(five sessions)
Administration 1 hour  
before CBT sessions 3–5
Placebo (50 mg) + CBT (five sessions) PDSS 
CGi-S for PD (global score,  
number and frequency of PAs,  
anticipatory anxiety, phobic  
avoidance, impairment of function)
1 week (post  
treatment)  
and 1 month  
(follow-up)  
following  
cessation of  
treatment
DCS had an augmentation effect on CBT 
efficacy 
PDSS and CGI-S decreased significantly in 
DCS group (vs placebo) post treatment, 
whereas no significant differences between 
groups were shown in follow-up
Siegmund  
et al68
Double-blind, randomized,  
placebo-controlled trial
DCS (50 mg) + CBT Administration once before CBT 
exposure sessions (only weeks  
2, 3, 4)
Placebo + CBT P&A 
BAi 
HAM-A
After 11 CBT  
sessions and  
at 1 and 5  
months after  
end of CBT
Both groups profited considerably from 
therapy and DCS did not significantly 
improve the outcome 
There was a statistical trend in the more 
severely ill patients that DCS accelerated 
symptom reduction post therapy
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
Palatnik69 Double-blind, randomized,  
controlled, crossover design
inositol (18 g/day) 4 weeks Fluvoxamine (150 mg/day) FQ 
Number of PAs (diary) 
HAM-A
weeks 3, 4, 5, 
6, 8, 9
Similar improvement in both groups on all 
measures, except for some superiority of 
inositol in reducing PAs
Abbreviations: ACQ, Agoraphobic Cognition Questionnaire; ADS, Anxiety Discomfort Scale; AG, agoraphobia; BAi, Beck Anxiety inventory; BDZ, benzodiazepine; 
CBT, cognitive behavioral therapy; CGi, Clinical Global impression; CGi-i, Clinical Global impression of improvement; CGi-S, Clinical Global impression of Severity; DCS, 
D-cycloserine; FQ, Fear Questionnaire; GPi, Global Patient’s impression scale; HAM-A, Hamilton Anxiety Rating Scale; MAOi, monoamine oxidase inhibitor; max, maximum; 
Mi-A, Mobility inventory for Agoraphobia; Mi-PF, Mobility inventory for Panic Frequency; NARi, selective noradrenergic reuptake inhibitor; ND, no data reported; P&A, 
Panic and Agoraphobia Scale; PA, panic attack; PAAS, Panic and Anticipatory Anxiety Scale; PASS, Panic Attack Symptoms Scale; PD, panic disorder; PDSS, Panic Disorder 
Severity Scale; SNRi, serotonin-norepinephrine reuptake inhibitor; SPAAS, Sheehan Panic Attack and Anxiety Scale; SSRi, selective serotonin reuptake inhibitor; TCA, tricyclic 
antidepressant; vs, versus; wL, waiting list.
the serotonergic system, thus potentially influencing several 
mechanisms involved in shaping agoraphobic behaviors, 
such as balance,33 light stimuli sensitivity,35 and condition-
ing processes;24 however, this idea remains speculative and 
should be tested in further studies.
Besides well-known antianxiety medications, new 
emerging drugs are being tested in AG with PD, with the 
main aim of enhancing the retention of therapeutic learning 
and fear extinction provided by exposure-based CBT. DCS 
has improved outcomes from exposure therapy in a virtual 
reality environment in height-phobic patients.75 DCS has 
shown mixed results in patients with PD and AG; in a recent 
study DCS appears to accelerate symptom reduction in more 
severely ill patients but fails to improve the outcome of CBT 
in the whole sample of patients with PD and AG.67 This 
does not confirm previous findings of its additive benefit as 
an augmentation strategy of CBT on phobic symptoms;66 
thus, further studies are warranted. Potential new effective 
compounds may enhance fear extinction by stimulating the 
activity of medial prefrontal cortical areas (mPFC), such as 
methylene blue (MB), which may have an indirect action 
on mPFC by increasing brain cytochrome oxidase activity, 
improving oxidative energy metabolism, and thereby supply-
ing the energy needs of synapses involved in consolidation 
of extinction memory.74 Clinical studies on the efficacy of 
MB for augmenting exposure-based treatments are currently 
underway.
The endocannabinoid system is another focus of research 
investigating new potential therapeutic approaches for anxi-
ety disorders. Indeed, cannabinoid (CB) receptors have been 
linked to extinction learning in animal models, type 1 CB 
(CB1) receptors have been found in brain areas related to 
anxiety and emotional learning (such as the amygdala and 
hippocampus),76 and CB1 antagonists lead to significant 
deficits in extinction learning,77 suggesting that CB receptor 
modulators may improve efficacy of exposure-based psy-
chotherapies in phobic syndromes;78 however, data are not 
available on PD with AG. Cortisol has been also proposed 
as an   augmentation strategy of extinction consolidation. 
Human and animal studies showed that acute increases of 
glucocorticoids can enhance emotional consolidation and 
extinction-based learning,79 the cortisol administration 
before virtual exposure to an acrophobic situation appeared 
to obtain a significantly greater fear reduction post treatment 
than placebo,80 and preliminary findings showed that the 
patients with PD and AG having least cortisol release during 
CBT exposures profited least from therapy.81 Finally, animal 
studies suggested that compounds with anticholinergic prop-
erties, acting in the primary sensory cortex, may improve 
sensory discrimination of the conditioned danger cue and its 
approximations; thus, a potential utility of these drugs on the 
fear-conditioned overgeneralization found in patients with PD 
has been proposed.15 Till now, no data have been available to 
evaluate the usefulness of these potential new compounds on 
AG and so future studies are needed.
Conclusion
Overall, there are several challenging issues in the pharma-
cological treatment of AG. First of all, a more stable and 
accepted psychopathological definition of AG is crucial to 
improve the search for specific treatments. Further neuro-
biological, functional imaging, and clinical studies are war-
ranted to better understand the pathogenesis of AG, either 
as a syndrome or as a distinct disorder, and, consequently, 
to better clarify the mechanisms of action and the usefulness 
of drugs. In PD with AG the clinical phenomena of phobic 
avoidance may not be simply related to spontaneous PAs; 
thus, potential specific effects of compounds on AG should 
be better tested, as well as new drugs that may have a specific 
efficacy, such as DCS. Finally, in clinical trials, patients with 
PD and AG are considered as a homogeneous group, without 
considering that different symptomatological profiles may 
exist, possibly reflecting multiple pathogenetic mechanisms 
involved in shaping agoraphobic behaviors.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 (Continued)
Pharmacological  
class
Reference Study characteristics Drug therapy (dosage)  
in experimental group
Duration of treatment 
administration
Control group(s) Outcome measures for AG  
and/or panic/anxiety
Timing of  
follow-up
Results
Palatnik69 Double-blind, randomized,  
controlled, crossover design
inositol (18 g/day) 4 weeks Fluvoxamine (150 mg/day) FQ 
Number of PAs (diary) 
HAM-A
weeks 3, 4, 5, 
6, 8, 9
Similar improvement in both groups on all 
measures, except for some superiority of 
inositol in reducing PAs
Abbreviations: ACQ, Agoraphobic Cognition Questionnaire; ADS, Anxiety Discomfort Scale; AG, agoraphobia; BAi, Beck Anxiety inventory; BDZ, benzodiazepine; 
CBT, cognitive behavioral therapy; CGi, Clinical Global impression; CGi-i, Clinical Global impression of improvement; CGi-S, Clinical Global impression of Severity; DCS, 
D-cycloserine; FQ, Fear Questionnaire; GPi, Global Patient’s impression scale; HAM-A, Hamilton Anxiety Rating Scale; MAOi, monoamine oxidase inhibitor; max, maximum; 
Mi-A, Mobility inventory for Agoraphobia; Mi-PF, Mobility inventory for Panic Frequency; NARi, selective noradrenergic reuptake inhibitor; ND, no data reported; P&A, 
Panic and Agoraphobia Scale; PA, panic attack; PAAS, Panic and Anticipatory Anxiety Scale; PASS, Panic Attack Symptoms Scale; PD, panic disorder; PDSS, Panic Disorder 
Severity Scale; SNRi, serotonin-norepinephrine reuptake inhibitor; SPAAS, Sheehan Panic Attack and Anxiety Scale; SSRi, selective serotonin reuptake inhibitor; TCA, tricyclic 
antidepressant; vs, versus; wL, waiting list.
In conclusion, there are too many critical issues around 
both the clinical definition of AG and the pharmacological 
studies available to give a clear answer regarding the best 
drug choice for the treatment of AG. Much more research 
is needed before a specific psychopharmacology of AG can 
be discussed.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Marks IM. The Agoraphobic Syndrome (Panic Disorder with Agora-
phobia). In: Fears, Phobia and Ritual. New York: Oxford University 
Press; 1987:323–361.
  2.  American Psychiatric Association, ed. Diagnostic and Statistical Man-
ual for Mental Disorders, Fourth Edition, Text Revision   (DSM-IV-TR). 
Washington, DC: American Psychiatric Association; 2000.
  3.  World Health Organization. ICD-10, International Statistical Classifica-
tion of Diseases and Related Health Problems. 10th ed. Arlington, VA: 
American Psychiatry Publishing; 1992.
  4.  Klein DF, Klein HM. The utility of the panic disorder concept. Eur 
Arch Psychiatry Neurol Sci. 1989;238(5–6):268–279.
  5.  Breier A, Charney DS, Heninger GR. Agoraphobia with panic attacks: 
development, diagnostic stability, and course of illness. Arch Gen 
Psychiatry. 1986;43(11):1029–1036.
  6.  Noyes R. The natural history of anxiety disorders. In Roth M, 
Noyes R Jr, Barrows GD, editors. Handbook of Anxiety: Biological, 
Clinical and Cultural Perspective. Vol 1. Amsterdam, The Netherlands: 
Elsevier Science Publishers; 1988:115–133.
  7.  Wittchen HU, Nocon A, Beesdo K, et al. Agoraphobia and panic: 
prospective-longitudinal relations suggest a rethinking of diagnostic 
concepts. Psychother Psychosom. 2008;77(3):147–157.
  8.  Fava GA, Rafanelli C, Tossani E, Grandi S. Agoraphobia is a disease: 
a tribute to Sir Martin Roth. Psychother Psychosom. 2008;77(3): 
133–138.
  9.  Faravelli C, Cosci F, Rotella F, Faravelli L, Catena Dell’osso M. Ago-
raphobia between panic and phobias: clinical epidemiology from the 
Sesto Fiorentino Study. Compr Psychiatry. 2008;49(3):283–287.
  10.  Perna G. Understanding anxiety disorders: from psychology to psy-
chopathology of defense mechanisms from threat. Riv Psichiatr. 2011.   
In press.
  11.  Wittchen HU, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG. 
Agoraphobia: a review of the diagnostic classificatory position and 
criteria. Depress Anxiety. 2010;27(2):113–133.
  12.  Perugi G, Frare F, Toni C. Diagnosis and treatment of agoraphobia with 
panic disorder. CNS Drugs. 2007;21(9):741–764.
  13.  Sugaya N, Kaiya H, Kumano H, Nomura S. Relationship between sub-
types of irritable bowel syndrome and severity of symptoms associated 
with panic disorder. Scand J Gastroenterol. 2008;43(6):675–681.
  14.  Michael T, Blechert J, Vriends N, Margraf J, Wilhelm FH. Fear 
  conditioning in panic disorder: enhanced resistance to extinction. 
J Abnorm Psychol. 2007;116(3):612–617.
  15.  Lissek S, Rabin S, Heller RE, et al. Overgeneralization of conditioned 
fear as a pathogenic marker of panic disorder. Am J Psychiatry. 2010; 
167(1):47–55.
  16.  Lissek S, Rabin SJ, McDowell DJ, et al. Impaired discriminative fear-
conditioning resulting from elevated fear responding to learned safety 
cues among individuals with panic disorder. Behav Res Ther. 2009; 
47(2):111–118.
  17.  Britton JC, Lissek S, Grillon C, Norcross MA, Pine DS. Development of 
anxiety: the role of threat appraisal and fear learning. Depress Anxiety. 
2011;28(1):5–17.
  18.  McTeague LM, Lang PJ, Laplante MC, Bradley MM. Aversive imagery 
in panic disorder: agoraphobia severity, comorbidity, and defensive 
physiology. Biol Psychiatry. 2011;70(5):415–424.
  19.  Zanoveli JM, Ferreira-Netto C, Brandão ML. Conditioned place aver-
sion organized in the dorsal periaqueductal gray recruits the laterodorsal 
nucleus of the thalamus and the basolateral amygdala. Exp Neurol. 2007; 
208(1):127–136.
  20.  Wittmann A, Schlagenhauf F, John T, et al. A new paradigm (Westphal-
Paradigm) to study the neural correlates of panic disorder with agora-
phobia. Eur Arch Psychiatry Clin Neurosci. 2011;261(3):185–194.
  21.  Critchley HD. The human cortex responds to an interoceptive challenge. 
Proc Natl Acad Sci U S A. 2004;101(17):6333–6334.
  22.  Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ.   Failure 
to regulate: counterproductive recruitment of top-down prefrontal-
subcortical circuitry in major depression. J Neurosci. 2007;27(33): 
8877–8884.
  23.  Pasquini M, Berardelli I. Anxiety levels and related pharmacological 
drug treatment: a memorandum for the third millennium. Ann Ist Super 
Sanita. 2009;45(2):193–204.
  24.  Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical 
hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157(4): 
493–505.
  25.  Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry. 
2007;12(2):120–150.
  26.  Vervliet B. Learning and memory in conditioned fear extinction: effects 
of D-cycloserine. Acta Psychol (Amst). 2008;127(3):601–613.
  27.  Luft T, Pereira GS, Cammarota M, Izquierdo I. Different time course for 
the memory facilitating effect of bicuculline in hippocampus, entorhinal 
cortex, and posterior parietal cortex of rats. Neurobiol Learn Mem. 
2004;82(1):52–56.
  28.  Perna G, Dario A, Caldirola D, Stefania B, Cesarani A, Bellodi L. Panic 
disorder: the role of the balance system. J Psychiatr Res. 2001;35(5): 
279–286.
  29.  Staab JP. Chronic dizziness: the interface between psychiatry and 
neuro-otology. Curr Opin Neurol. 2006;19(1):41–48.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
636
Perna et al
  30.  Redfern MS, Furman JM, Jacob RG. Visually induced postural sway 
in anxiety disorders. J Anxiety Disord. 2007;21(5):704–716.
  31.  Caldirola D, Teggi R, Bondi S, et al. Is there a hypersensitive visual alarm 
system in panic disorder? Psychiatry Res. 2011;187(3):387–391.
  32.  Brandt T. Phobic postural vertigo. Neurology. 1996;46(6):1515–1519.
  33.  Löscher W. Abnormal circling behavior in rat mutants and its relevance 
to model specific brain dysfunctions. Neurosci Biobehav Rev. 2010; 
34(1):31–49.
  34.  Lourenco SF, Longo MR, Pathman T. Near space and its relation to 
claustrophobic fear. Cognition. 2011;119(3):448–453.
  35.  Kellner M, Wiedemann K, Zihl J. Illumination perception in photo-
phobic patients suffering from panic disorder with agoraphobia. Acta 
Psychiatr Scand. 1997;96(1):72–74.
  36.  Castrogiovanni P, Pieraccini F, Iapichino S, et al. Electroretinogram 
B-wave amplitude in panic disorder. CNS Spectr. 2001;6(3):210–213.
  37.  Purdy RA. The role of the visual system in migraine: an update. Neurol 
Sci. 2011;32 Suppl 1:S89–S93.
  38.  Yamada K, Moriwaki K, Oiso H, Ishigooka J. High prevalence of 
comorbidity of migraine in outpatients with panic disorder and effec-
tiveness of psychopharmacotherapy for both disorders: a retrospective 
open label study. Psychiatry Res. 2011;185(1–2):145–148.
  39.  Teggi R, Caldirola D, Colombo B, et al. Dizziness, migrainous vertigo 
and psychiatric disorders. J Laryngol Otol. 2010;124(3):285–290.
  40.  Van Apeldoorn FJ, Timmerman ME, Mersch PP, et al. A randomized 
trial of cognitive-behavioral therapy or selective serotonin reuptake 
inhibitor or both combined for panic disorder with or without agora-
phobia: treatment results through 1-year follow-up. J Clin Psychiatry. 
2010;71(5):574–586.
  41.  National Institute for Health and Clinical Excellence (NICE). 
  Generalised anxiety disorder and panic disorder (with or without 
agoraphobia) in adults: management in primary, secondary and com-
munity care. NICE clinical guideline 113; Jan 2011. Available at: http://
www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf. Accessed on 
September 15, 2011.
  42.  Van Apeldoorn FJ, van Hout WJ, Mersch PP, et al. Is a combined therapy 
more effective than either CBT or SSRI alone? Results of a multicenter 
trial on panic disorder with or without agoraphobia. Acta Psychiatr 
Scand. 2008;117(4):260–270.
  43.  Toni C, Perugi G, Frare F, Mata B, Akiskal HS. Spontaneous treatment 
discontinuation in panic disorder patients treated with antidepressants. 
Acta Psychiatr Scand. 2004;110(2):130–137.
  44.  Mavissakalian MR, Perel JM. 2nd year maintenance and discontinuation 
of imipramine in panic disorder with agoraphobia. Ann Clin Psychiatry. 
2001;13(2):63–67.
  45.  Mavissakalian MR, Perel JM. Duration of imipramine therapy and 
relapse in panic disorder with agoraphobia. J Clin Psychopharmacol. 
2002;22(3):294–299.
  46.  Marchand A, Coutu MF, Dupuis G, et al. Treatment of panic disorder 
with agoraphobia: randomized placebo-controlled trial of four psycho-
social treatments combined with imipramine or placebo. Cogn Behav 
Ther. 2008;37(3):146–159.
  47.  Bandelow B, Broocks A, Pekrun G, et al. The use of the Panic and Ago-
raphobia Scale (P&A) in a controlled clinical trial.   Pharmacopsychiatry. 
2000;33(5):174–181.
  48.  Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L. 
Antipanic drug modulation of 35% CO2 hyperreactivity and short-term 
treatment outcome. J Clin Psychopharmacol. 2002;22(3):300–308.
  49.  Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic 
response in panic disorder: moclobemide, a case in point. J Clin Psy-
chopharmacol. 2002;22(3):275–284.
  50.  Valença AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, 
Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. 
Arq Neuropsiquiatr. 2000;58(4):1025–1029.
  51.  Valença AM, Nardi AE, Mezzasalma MA, et al. Therapeutic response 
to benzodiazepine in panic disorder subtypes. Sao Paulo Med J. 2003; 
121(2):77–80.
  52.  Katzelnick DJ, Saidi J, Vanelli MR, Jefferson JW, Harper JM, 
McCrary KE. Time to response in panic disorder in a naturalistic setting: 
combination therapy with alprazolam orally disintegrating tablets and 
serotonin reuptake inhibitors compared to serotonin reuptake inhibitors 
alone. Psychiatry (Edgmont). 2006;3(12):39–49.
  53.  Uhlenhuth EH, Matuzas W, Warner TD, Paine S, Lydiard RB, 
Pollack MH. Do antidepressants selectively suppress spontaneous 
(unexpected) panic attacks? A replication. J Clin Psychopharmacol. 
2000;20(6):622–627.
  54.  Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, 
double-blind, placebo-controlled study of the effects of adjunctive par-
oxetine in panic disorder patients unsuccessfully treated with cognitive-
behavioral therapy alone. J Clin Psychiatry. 2002;63(9):772–777.
  55.  Hendriks GJ, Keijsers GP, Kampman M, et al. A randomized controlled 
study of paroxetine and cognitive-behavioural therapy for late-life panic 
disorder. Acta Psychiatr Scand. 2010;122(1):11–19.
  56.  Wedekind D, Broocks A, Weiss N, Engel K, Neubert K, Bandelow B. 
A randomized, controlled trial of aerobic exercise in combination with 
paroxetine in the treatment of panic disorder. World J Biol Psychiatry. 
2010;11(7):904–913.
  57.  Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in 
the treatment of panic disorder: an acute, double-blind noninferiority 
comparison. J Clin Psychiatry. 2004;65(3):405–413.
  58.  Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: 
a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 
2003;64(11):1322–1327.
  59.  Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improve-
ment of quality of life in panic disorder with escitalopram, citalopram, 
or placebo. Pharmacopsychiatry. 2007;40(4):152–156.
  60.  Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison 
of citalopram and paroxetine in the treatment of panic disorder: a ran-
domized, single-blind study. Pharmacopsychiatry. 2001;34(3):85–90.
  61.  Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepi-
nephrine reuptake inhibitor, is an effective and well-tolerated treatment 
for panic disorder. J Clin Psychiatry. 2002;63(1):31–37.
  62.  Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment 
with paroxetine and reboxetine in panic disorder: a randomized, single-
blind study. Pharmacopsychiatry. 2004;37(5):206–210.
  63.  Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the 
efficacy of venlafaxine extended-release, paroxetine, and placebo in 
the treatment of panic disorder. Depress Anxiety. 2007;24(1):1–14.
  64.  Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study 
of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 
2000;20(4):467–471.
  65.  Sandford JJ, Forshall S, Bell C, et al. Crossover trial of pagoclone and 
placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 
2001;15(3):205–208.
  66.  Otto MW, Tolin DF, Simon NM, et al. Efficacy of D-cycloserine for 
enhancing response to cognitive-behavior therapy for panic disorder. 
Biol Psychiatry. 2010;67(4):365–370.
  67.  Siegmund A, Golfels F, Finck C, et al. D-cycloserine does not improve 
but might slightly speed up the outcome of in-vivo exposure therapy in 
patients with severe agoraphobia and panic disorder in a randomized 
double blind clinical trial. J Psychiatr Res. 2011;45(8):1042–1047.
  68.  Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, 
crossover trial of inositol versus fluvoxamine for the treatment of panic 
disorder. J Clin Psychopharmacol. 2001;21(3):335–339.
  69.  Mitte K. A meta-analysis of the efficacy of psycho- and pharmaco-
therapy in panic disorder with and without agoraphobia. J Affect Disord. 
2005;88(1):27–45.
  70.  Otto MW, Bruce SE, Deckersbach T. Benzodiazepine use, cognitive 
impairment, and cognitive-behavioral therapy for anxiety disorders: 
issues in the treatment of a patient in need. J Clin Psychiatry. 2005; 
66 Suppl 2:34–38.
  71.  Levine J. Controlled trials of inositol in psychiatry. Eur Neuro-
psychopharmacol. 1997;7(2):147–155.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
637
Antianxiety medications for the treatment of complex agoraphobia
  72.  Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. 
  Double-blind, placebo-controlled, crossover trial of inositol treatment 
for panic disorder. Am J Psychiatry. 1995;152(7):1084–1086.
  73.  Perna G, Alpini D, Caldirola D, Raponi G, Cesarani A, Bellodi L. 
Serotonergic modulation of the balance system in panic disorder: an 
open study. Depress Anxiety. 2003;17(2):101–106.
  74.  Kaplan GB, Moore KA. The use of cognitive enhancers in animal models 
of fear extinction. Pharmacol Biochem Behav. 2011;99(2):217–228.
  75.  Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers 
as adjuncts to psychotherapy: use of D-cycloserine in phobic individu-
als to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11): 
1136–1144.
  76.  Moreira FA, Lutz B. The endocannabinoid system: emotion, learning 
and addiction. Addict Biol. 2008;13(2):196–212.
  77.  Hernandez G, Cheer JF. Extinction learning of rewards in the rat: is there 
a role for CB1 receptors? Psychopharmacology (Berl). 2011;217(2): 
189–197.
  78.  Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing can-
nabinoid neurotransmission augments the extinction of conditioned 
fear. Neuropsychopharmacology. 2005;30(3):516–524.
  79.  Otto MW, McHugh RK, Kantak KM. Combined pharmacotherapy and 
cognitive-behavioral therapy for anxiety disorders: medication effects, 
glucocorticoids, and attenuated outcomes. Clin Psychol Sci Prac. 
2010;17(2):91–103.
  80.  de Quervain DJ, Bentz D, Michael T, et al. Glucocorticoids enhance 
extinction-based psychotherapy. Proc Natl Acad Sci U S A. 2011; 
108(16):6621–6625.
  81.  Siegmund A, Köster L, Meves AM, Plag J, Stoy M, Ströhle A. Stress 
hormones during flooding therapy and their relationship to therapy 
outcome in patients with panic disorder and agoraphobia. J Psychiatr 
Res. 2011;45(3):339–346.